• Home
  • About OTI
    • Mission
    • Vision
    • History
    • Contact Us
  • Pipelines & Partners
  • Breakthrough Therapy
  • Glaucoma
  • Team
  • News
  • Publications
  • Louis B. Cantor
  • Clive Wilson
  • James C Tsai
  • More
    • Home
    • About OTI
      • Mission
      • Vision
      • History
      • Contact Us
    • Pipelines & Partners
    • Breakthrough Therapy
    • Glaucoma
    • Team
    • News
    • Publications
    • Louis B. Cantor
    • Clive Wilson
    • James C Tsai

  • Home
  • About OTI
    • Mission
    • Vision
    • History
    • Contact Us
  • Pipelines & Partners
  • Breakthrough Therapy
  • Glaucoma
  • Team
  • News
  • Publications
  • Louis B. Cantor
  • Clive Wilson
  • James C Tsai

Publications

Understanding the Biology in Current Cell and Gene Therapy for Treating Macular Diseases

 Guanting Qiu T (2023) . Macular Diseases - An Update. IntechOpen. 

 https://www.intechopen.com/online-first/1163128 

Trabodenoson on trabecular meshwork rejuvenation: a comprehensive review of clinical data

 Qiu TG. Expert Opin Investig Drugs. 2021 Mar;30(3):227-236. doi: 10.1080/13543784.2021.1873276. Epub 2021 Jan 21. PMID: 33405971. 

 https://www.tandfonline.com/doi/full/10.1080/13543784.2021.1873276 


McDonnell F, Perkumas KM, Ashpole NE, Kalnitsky J, Sherwood JM, Overby DR, Stamer WD. Shear Stress in Schlemm's Canal as a Sensor of Intraocular Pressure. Sci Rep. 2020 Apr 2;10(1):5804. https://www.nature.com/articles/s41598-020-62730-4

Transplantation of human embryonic stem cell-derived retinal pigment epithelial cells (MA09-hRPE) in

 Qiu TG. NPJ Regen Med. 2019 Aug 27;4:19. doi: 10.1038/s41536-019-0081-8. PMID: 31482011; PMCID: PMC6712006. 

 https://www.nature.com/articles/s41536-019-0081-8 

The Global Ophthalmology Meeting Presentations

OTI Presented at 2024 Ophthalmology -Future Forum: https://vimeo.com/1008380727

OTI Presented at 2023 Ophthalmology -Future Forum: https://vimeo.com/1008380727

https://www.ophthalmology-futures.com/forums/

Durysta derived MMP Therapy on HVF Stability and Drug Holiday.

Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2)
Bacharach J, Tatham A, Ferguson G, Belalcázar S, Thieme H, Goodkin ML, Chen MY, Guo Q, Liu J, Robinson MR, Bejanian M, Wirta DL; ARTEMIS 2 Study Group. Drugs. 2021 Nov;81(17):2017-2033. https://pubmed.ncbi.nlm.nih.gov/34724172/

Downloads

June 11 2025 OTI Milestone Update -Bridge Funding (pdf)Download
May 23 2025 Patent update to OTI taksforoce -1 (pdf)Download
OTI newsletter 02.19.2025 (pdf)Download
January 6 2025 OTI Update -Billion $ Molecule Big Data Pioneer (pdf)Download
2024 Year in Review OTI-V1 (pdf)Download
Investor Q & A with OTI-2024 Trabodenoson (pdf)Download
Investor One Page Wefunder (pdf)Download

© OTI 2026 -  All Rights Reserved.


Powered by

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept